Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients by unknown
RESEARCH ARTICLE Open Access
Serum HER2 extra-cellular domain, S100ß
and CA 15-3 levels are independent
prognostic factors in metastatic breast
cancer patients
Amélie Darlix1*, Pierre-Jean Lamy2,3, Evelyne Lopez-Crapez4, Antoine Laurent Braccini5, Nelly Firmin1,
Gilles Romieu1, Simon Thezenas6 and William Jacot1
Abstract
Background: Metastatic breast cancer (MBC) prognosis is highly variable, depending on various factors such as the
biological subtype, the performance status, disease extension…. A better evaluation of a patient’s prognostic factors
could allow for a more accurate choice of treatments. The role of serum tumor markers remains, however, unclear
in this population. Considering the recent interest in phenotypic changes and tumor heterogeneity during breast
cancer progression, additional tumor markers could be interesting in this setting.
Methods: Two hundred fifty MBC patients treated at the Montpellier Cancer Institute (2008–2015) were retrospectively
selected, based on the availability of frozen serum samples. The usual MBC clinical and pathological variables were
collected, altogether with Cancer Antigen 15-3 (CA15-3), Carcinoembryonic Antigen (CEA), HER2 extra-cellular domain
(ECD), Neuron Specific Enolase (NSE), S100ß protein and Matrix Metalloproteinase 9 (MMP-9) serum levels in order to
determine their prognostic value.
Results: With a median follow-up of 40.8 months, median overall survival was 16.2 months (95 % CI 12.4–20.6). In
multivariate analysis, the performance status, brain or subcutaneous metastases, the number of previous metastatic
chemotherapy lines and the tumor biological subtype were independent prognostic factors. Elevated CA 15-3 (HR = 1.
95, IC 95 % 1.31–2.93, p = 0.001), HER2 ECD (regardless of tumor HER2 status, HR = 2.51, IC 95 % 1.53–4.12, p < 0.001)
and S100ß (HR = 1.93, IC 95 % 1.05–3.54, p = 0.033) serum levels were independently associated with a poor outcome.
Conclusions: Serum CA 15-3, HER2 ECD and S100ß could represent useful independent prognostic factors in MBC. Of
particular interest is the independent value of serum HER2 ECD levels, regardless of the tumor HER2 status, possibly
linked to metastatic tumor heterogeneity.
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Background
The survival of patients with metastatic breast cancer
(MBC) has improved over the past decades with the use
of new therapeutic agents [1]. However, the outcome re-
mains poor (median overall survival [OS] of 21–30
months) [1, 2]. MBC prognosis is highly variable de-
pending on various factors, with survivals ranging from
a few months to decades. This variability probably re-
flects the biological heterogeneity among MBC [3]. In-
deed, in a study on 1 038 MBC patients, the median OS
was 27 months for tumors with overexpression of hor-
mone receptors (HR) (HR-positive tumors) compared
with 9 months for HR-negative tumors [4]. Likewise, the
median OS for HER2 (Human epidermal growth factor
receptor 2)-positive/HR-positive tumors and triple nega-
tive tumors were 34.4 and 8.8 months, respectively, in a
series of 815 MBC patients [5]. Given this important
variability in terms of outcomes, a better evaluation of a
given patient’s prognostic factors could allow for a more
accurate choice of the therapeutic strategy.
To date, several clinical and biological prognostic fac-
tors have been reported, including patients’ characteris-
tics (age and performance status), previous medical
history (prior chemotherapy [CT] for MBC treatment),
disease extension (number and location of metastatic
sites) and tumor biology. A high number of metastatic
sites, the presence of visceral metastases compared to
bone and/or soft tissue metastases only, and the pres-
ence of liver or brain metastases (BM) are clinical fea-
tures associated with a poor outcome in various studies
[4–6]. Tumor biology remains a cornerstone of patients’
prognosis, linked to prognostic and predictive factors
(HR and HER2 expression). HR-positive tumors have
been associated with a better outcome, and with re-
sponse to hormone therapy [4, 7, 8]. Regarding the
HER2 status, series from the pre-Trastuzumab era have
demonstrated a negative prognostic value of the HER2
amplification in MBC [9]. Since the introduction of
Trastuzumab, however, this effect has been reversed and
HER2 amplification has been associated with a better
outcome in recent series [5, 10]. In the series published
by Dawood et al., patients with HER2-positive MBC re-
ceiving Trastuzumab had a better outcome than patients
with HER2-positive MBC not receiving Trastuzumab, or
than patients with HER2-negative MBC [10]. Overall,
the different biological subtypes according to the HR
and HER2 statuses have been correlated with variable
prognosis in MBC as well as in early breast cancer
(EBC) [5]. High Lactate Dehydrogenase (LDH) and low
albumin serum levels have also been reported as poor
prognostic factors in MBC in several studies [11–13].
The role of serum tumor markers in predicting outcome
remains, however, unclear in patients with MBC. High
Cancer Antigen 15-3 (CA 15-3) and Carcinoembryonic
Antigen (CEA) serum levels seem to be associated with a
poorer survival [14–16]. The prognostic value of serum
HER2 extra-cellular domain (ECD) has been shown in
HER2-positive MBC patients, high serum HER2 ECD levels
being associated with a poor outcome [17, 18]. Few studies
have investigated this question in HER-negative tumors:
some authors have suggested a prognostic value of the
serum HER2 ECD in HER2-negative tumors as well [19].
Other biomarkers have been investigated to predict
outcome in MBC patients, including circulating tumor
cells and growth factors [14, 18]. Considering the recent
interest in phenotypic changes and tumor heterogeneity
during breast cancer progression, it could be interesting to
evaluate additional tumor markers in this setting to better
assess tumor heterogeneity in a non-invasive manner.
Among these biomarkers, the Neuron Specific Enolase
(NSE), a neuronal marker, seems a good candidate. An
elevated serum NSE level in MBC could reflect either a
neuroendocrine differentiation of the tumor or a central
nervous system extent of the disease, and be linked with
poor outcome. Serum NSE has been studied in small-
cell lung cancers, and in various neurological conditions
such as stroke or Creutzfeld-Jakob disease [20–22].
However, to our knowledge, its prognostic value has
never been investigated in MBC.
The Matrix Metalloproteinase 9 (MMP-9), a proteo-
lytic enzyme that degrades the extra-cellular matrix
components, is involved in tumor invasion and meta-
static dissemination [23]. Its serum level has been asso-
ciated with several solid tumors including breast cancer
[24–26]. In breast cancer, it has been correlated with
poor prognostic in one study only [25]. Moreover, a re-
cent study on gastric cancer has reported interactions
between MMP-9 and HER2 in invasion processes [27].
The serum S100ß protein is involved in cell proliferation
[28]. Its prognostic value has been demonstrated in melan-
oma [29]. Being an astrocytic marker, its elevation in serum
is a marker for an alteration of the blood-brain barrier.
Therefore, serum S100ß has been widely studied in various
neurological diseases [21, 30]. Due to the high frequency of
asymptomatic central nervous system involvement in
breast cancer, serum S100ß could have a prognostic value
and be an interesting serum biomarker in MBC [31].
The aim of the present study was to evaluate the prog-
nostic value of serum tumor markers, namely CA15-3,
CEA, HER2 ECD, NSE, MMP-9 and S100ß in a series of
MBC patients. We hypothesized that these biomarkers
serum levels were significantly associated with OS.
Methods
Design
We conducted a retrospective, monocentric study on
MBC patients treated at the Montpellier Cancer Insti-
tute between 2008 and 2015.
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Patients
MBC patients were retrospectively identified for the pur-
poses of a case-control study conducted by our team in
MBC patients with BM (submitted), by reviewing the
medical records of the MBC patients from the Montpel-
lier Cancer Institute database between 2008 and 2015. In-
clusion criteria were: patient ≥ 18 years old; histologically-
confirmed MBC; availability of the HR and HER2 statuses
of the primary tumor; availability of a frozen serum sam-
ple performed at the metastatic phase, for biomarker de-
termination. Patients with history of other cancer(s) were
excluded.
Objectives
The primary objective was to evaluate the prognostic
value of six serum biomarkers (namely, CA 15-3, CEA,
HER2 ECD, NSE, MMP-9 and S100ß) in patients with
MBC. The secondary objectives were to evaluate the
prognostic value of other usual clinical and biological
prognostic factors.
Clinical and biological data
Clinical and biological data were collected by reviewing
the medical records of the selected patients: demograph-
ical, clinical (date of diagnosis of breast cancer and
metastatic disease; metastatic status at diagnosis; inflam-
matory breast cancer; treatment history), and biological
data (histological grade of the primary tumor, HR and
HER2 statuses). The tumor was considered HR-positive
when more than 10 % of cells were labeled in immuno-
histochemistry (IHC) or when the concentrations of es-
trogen (ER) and progesterone receptors (PR) using the
radio ligand binding method were above 10 ng/mL and
50 ng/mL, respectively. The tumor was considered
HER2-positive if the primary tumor was scored 3+ by
IHC or if the HER2 gene was amplified by fluorescence
or chromogenic in situ hybridization (FISH/CISH) for
IHC 2+ cases. For cases with HR and/or HER2 statuses
changes over time, the biology used was that of the most
recent sample. For cases of synchronous or asynchron-
ous bilateral cancer with discrepant HR and/or HER sta-
tuses, the most unfavorable biology was used: higher
histological grade, HR-negative, HER2-negative (Trastu-
zumab era).
Analysis of serum biomarkers
The selected serum samples were extracted from the
Biological Resource Center of the Montpellier Cancer
Institute (Biobank number BB-0033-00059) (samples
processed within one hour after sampling and stored at
−80 °C in serum aliquots). The biologists performing the
analyses were blinded to the study endpoints. HER2 ECD,
NSE and MMP-9 serum levels were measured by ELISA
using commercially available ELISA assays (Human
MMP-9 Quantikine Kit R&D Systems, Minneapolis, MN,
USA for MMP-9, ELSA-NSE RIA kit, Cisbio assays, Gif
sur Yvette, France for NSE, and Nuclea Diagnostic La-
boratories kit, LLC for HER2 ECD) according to the man-
ufacturer’s instructions. For MMP-9, a duplicate analysis
was performed, but no duplicate analyses were deemed
necessary. S100ß serum levels were measured with the
Elecsys S100 Immunoassay (Roche Diagnostics GmbH,
Mannheim, Germany). Other biological parameters, in-
cluding CA 15-3 (ELSA-CA15-3 Cisbio assays Gif sur
Yvette France) and CEA (Elecsys CEA test Roche Diag-
nostics, Meylan, France), had previously been analyzed for
clinical purposes and were collected. As we evaluated the
prognostic value of biomarkers, the manuscript adheres to
the REMARK guidelines.
Statistical analysis
Categorical variables were reported: number of missing
data, number and percentage for each variable modality.
For continuous variables, number of missing data, mean,
standard deviation, median and range values were com-
puted. OS delay was measured from the date of the
serum sample to the date of death from any cause. Pa-
tients alive without events were censored at the closing
date of the study analysis (March 30th, 2015). The OS
was estimated according to the Kaplan-Meier method,
and presented as medians with their 95 % confidence in-
tervals (95 % CIs) and survival rates (in percent, with
95 % CIs) [32]. The median duration of follow-up was
estimated using a reverse Kaplan-Meier method and
presented with its 95 % CIs. As there are no validated
cut-offs in MBC patients, different cut-offs reported in
previous studies were used to investigate the prognostic
value of the serum HER2 ECD (cut-offs 15 ng/mL and
30 ng/mL [17, 33]), NSE (cut-off 12.5 μg/L [34]), MMP-
9 (cut-off 50 ng/mL [35]) and S100ß (cut-offs 0.12 μg/L
and 0.072 μg/L [33]). The following cut-offs were used for
the usual breast cancer biomarkers: 30 U/mL for CA 15-3
and 10 ng/mL for CEA. To investigate prognostic factors,
a multivariate analysis was performed using the Cox’s pro-
portional hazards regression model with a stepwise pro-
cedure. Hazard ratios (HR) with 95 % CIs were calculated
to display risk changes. All p values reported were two-
sided, and the significance level was set at 5 % (p < 0.05).
Statistical analysis was performed using the STATA 13
software (Stata Corporation, College Station, TX).
Ethical considerations
This study was reviewed and approved by the Montpellier
Cancer Institute Institutional Review Board (ID number
ICM-URC-2014/73). Considering the retrospective, non-
interventional nature of this study, no specific consent
was deemed necessary by the clinical research review
board of the Montpellier Cancer Institute.
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Results
Patients’ characteristics
A total of 250 women with MBC were included in the
study. The clinical and biological characteristics of pa-
tients at baseline are presented in Table 1. Median age at
the time of the serum sample was 58.4 years old (range
26.4–87.2). The most represented histological subtype
was ductal carcinoma in 82.9 % of cases. Tumor biology
was distributed as follows: HER2+/HR+ in 23.2 %, HER2
+/HR- in 24.4 %, HER2-/HR+ in 25.6 % and triple nega-
tive in 26.8 % of cases. Among the 250 patients, 70 pre-
sented with synchronous metastases at breast cancer
first diagnosis. The median number of previous chemo-
therapy (CT) lines was 1 (range 0–9; no previous CT
24.4 %, one or two CT lines 45.2 %, and more than two
CT lines 30.4 %). 40.4 % of patients had received a previ-
ous anti-HER2 treatment (83.2 % of patients with a
HER2-positive tumor). The metastatic-free interval
(MFI) was over 24 months for 55.6 % of patients. At the
time of the serum sample, 60.8 % of patients had liver
metastases, 56.8 % bone metastases, 53.6 % lymph nodes
metastases, 50.0 % had lung metastases, 35.2 % of pa-
tients had BM, 22.0 % pleural metastases, 17.2 % had
subcutaneous metastases and 43.6 % had metastases at
other sites. A vast majority of patients had at least two
metastatic sites (86.0 %). Only 13 patients (5.2 %) had
only bone and/or subcutaneous metastases. Most pa-
tients had a good performance status (ECOG status ≤ 2
in 90.6 %). Albumin serum level was available for 158
(63.2 %) patients and was low in 23 cases (14.6 %).
Serum LDH level was high in 43.3 % of the 90 cases with
a reported value.
Serum CA 15-3, CEA, HER2 ECD, NSE, MMP-9 and S100ß
The median serum biomarker levels were: 38.0 U/mL
(range 8.0–1988.0) for CA 15-3, 4.0 ng/mL (range 1.0–
5122.0) for CEA, 13.6 ng/mL (range 2.8–280.0) for
HER2 ECD, 9.0 μg/L (range 1.9–57.3) for NSE,
341.0 ng/mL (range 38.7–2051.0) for MMP-9 and
0.05 μg/L (range 0.0–0.6) for S100ß. The proportion of
patients with high values is presented for each serum
tumor marker in Table 1. Serum CA 15-3 and CEA were
elevated in 60.3 % and 33.6 % of the 232 patients with
known values. Serum HER2 ECD (cut-off 15 ng/mL)
and MMP-9 (cut-off 50 ng/mL) were elevated in 42.8 %
and 97.6 % of the 250 patients with known values, re-
spectively. Serum NSE was high in 30.5 % of the 249 pa-
tients with known values, and serum S100ß (cut-off
0.12 μg/L) in 7.8 % of the 243 patients with known
values. All but two patients had at least one elevated
biomarker among S100ß, NSE, MMP-9 or HER ECD
(when using cut-offs at 15 ng/mL for HER ECD and
0.12 μg/L for S100ß).
Prognostic factors
At the time of the analysis, 69.2 % of patients had died,
mostly because of MBC progression (87.9 %). With a
median follow-up of 40.8 months, median OS was
16.2 months (95 % CI 12.4–20.6). The 1-year and 2-year
survival rates were 57.1 % (95 % CI 50.6–63.1) and
38.5 % (95 % CI 32.1–44.9), respectively. The following
variables were significant poor prognostic determinants
in univariate analysis (Table 2): grade 3 tumors (p =
0.02), PR-negative tumors (p = 0.03), ER-negative tumors
(trend, p = 0.09), HER2-negative tumors (p < 0.001),
metachronous metastatic disease (p = 0.01), existence of
two or more metastatic sites (p < 0.001), visceral metas-
tases (compared with bone and/or subcutaneous metas-
tases only) (p = 0.001), liver metastases (p < 0.001), BM
(p < 0.001), subcutaneous metastases (p = 0.006), metas-
tases from other sites (p < 0.001), number of previous
metastatic CT lines >2 (p < 0.001), no previous anti-
HER2 treatment (p < 0.001), poor ECOG performance
status (p < 0.001), and low albumin levels (p < 0.001)
(Fig. 1). Among the tested biomarkers, high CEA (p =
0.001), high CA 15-3 (p < 0.001), high NSE (p < 0.001),
high HER2 ECD (p < 0.001 with cut-offs at 15 ng/mL
and 30 ng/mL), high S100ß (p < 0.001 with cut-offs at
0.12 μg/L and 0.072 μg/L) and high MMP-9 (p = 0.009)
serum levels were also poor prognostic determinants in
univariate analysis (Fig. 1). The prognostic value of
serum HER2 ECD (with cut-offs 15 and 30 ng/mL) was
significant in patients with HER2-positive tumors as well
as in the HER2-negative tumors group (p < 0.0001 and p
= 0.005, respectively, with cut-off 15 ng/mL) (Fig. 2). A
multivariate analysis was performed (n = 208), excluding
albumin due to a high number of missing data. The
ECOG performance status, the presence of BM or sub-
cutaneous metastases, the number of previous metastatic
CT lines, the tumor biological subtype, and high serum
CA 15-3, S100ß (cut-off at 0.12 μg/L) and HER2 ECD
(cut-off at 30 ng/mL) levels were independently associ-
ated with poor prognosis (Table 3). We performed an-
other analysis considering the biomarkers as continuous
variables and confirmed that high serum CEA (p <
0.001), CA15-3 (p = 0.003), NSE (p < 0.001), HER2 ECD
(p = 0.009) and S100ß (p < 0.000), but not MMP-9 (p =
0.476), were significantly associated with survival in uni-
variate analysis. In multivariate analysis, HER2 ECD and
S100ß, but not CA 15-3, remained independent prog-
nostic factors (p = 0.004 and p < 0.001, respectively).
Discussion
Prognostic value of serum CA15-3, HER2 ECD and S100ß
Our study confirmed the prognostic value of serum CA
15-3 [14–16]. On the contrary, serum CEA, that has
previously been associated with worse outcome (pro-
gression-free survival and OS) in several studies, was
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Table 1 Patients’ clinical and biological characteristics
Initial characteristics
Tumor biology group, n (%)
HER2+ HR+ 58 (23.2)
HER2+ HR- 61 (24.4)
HER2- HR+ 64 (25.6)
Triple negative 67 (26.8)
ER status, n (%)
Negative 128 (51.2)
Positive 122 (48.8)




HER2 status, n (%)
Negative 131 (52.4)
Positive 119 (47.6)
Histological subtype, n (%)
Ductal carcinoma 203 (82.9)
Other subtypesa 42 (17.1)
Missing 5
Histological grade (SBR), n (%)
1 or 2 103 (45.8)
3 122 (54.2)
Missing 25








Patients’ characteristics at the time of the serum sample
Median age in years (range) 58.4 (26.4–87.2)
Age group, n (%)
< 50 77 (30.8)
50 to 70 132 (52.8)
> 70 41 (16.4)
Median number of lines of CT (range) 1 (0–9)
Number of lines of CT, n (%)
0 line 61 (24.4)
1 or 2 line(s) 113 (45.2)
> 2 lines 76 (30.4)
Table 1 Patients’ clinical and biological characteristics (Continued)
Previous anti-HER2 treatment, n (%)
No 149 (59.6)
Yes 101 (40.4)
Brain metastases, n (%) 88 (35.2)
Liver metastases, n (%) 152 (60.8)
Bone metastases, n (%) 142 (56.8)
Lung metastases, n (%) 125 (50.0)
Lymph node metastases, n (%) 134 (53.6)
Subcutaneous metastases, n (%) 43 (17.2)
Pleural metastases, n (%) 55 (22.0)
Metastases of other sites, n (%) 109 (43.6)






























Elevated serum CEA, n (%)
No 154 (66.4)
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correlated with poor prognosis in univariate but not
multivariate analysis. This result is possibly linked to a
preponderant effect of other more robust prognostic fac-
tors [14–16].
In addition to the prognostic value of CA 15-3, our
study showed that high serum HER2 ECD and S100ß
levels were independent unfavorable prognostic factors
in MBC patients. The prognostic value of serum HER2
ECD appeared significant not only in HER2-positive tu-
mors but also in HER2-negative tumors (p = 0.03). Dis-
cordance between the tumor HER2 status and the HER2
level have been previously reported [36]. In our study,
44 patients (33.6 %) with a HER2-negative tumor had an
elevated serum HER2 ECD (≥15 ng/mL). The prognostic
impact of serum HER2 ECD has already widely been
studied in patients with HER2-positive MBC [17, 18].
However, it has been less frequently investigated in pa-
tients with HER2-negative MBC, with only few studies
suggesting a prognostic value in this population as well
[19]. Our result could have different explanations. First,
it could be linked to phenotypic MBC heterogeneity,
some tumor cells displaying HER2 overexpression
among HER2-negative MBC [37]. It could also be due to
changes in the HER2 status along tumor progression.
However this phenomenon seems to be a rare event [38,
39]. In a recent study, discrepancies between the primary
tumor and distant metastases as regards to the HER2
status were observed in only 8 % of cases [40]. Moreover,
we collected the most recent tumor biology data, as
some phenotypic changes are possible between the initial
tumor and metastatic recurrences. Finally, it has been
recently shown that some HER2-negative tumors (tu-
mors that do not overexpress the HER2 ECD) are posi-
tive for the intracellular domain of HER2 and/or show
an amplification of the HER2 gene [41]. In the study
published by Panis et al., this group of patients (16 % of
the patients with a HER2-negative tumor) had a survival
similar to that of HER2-positive tumor patients. More-
over, the PI3K expression and the AKT pathway activa-
tion were similar to that of HER2-positive tumors. This
Table 1 Patients’ clinical and biological characteristics (Continued)
Yes 78 (33.6)
Missing 18





































Status as last follow-up, n (%)
Alive 77 (30.8)
Dead 173 (69.2)
Table 1 Patients’ clinical and biological characteristics (Continued)
Cause of death, n (%) (174 deceased)




Abbreviations: ER estrogen-receptors, PR progesterone-receptors, SBR Scarf,
Bloom and Richardson, BC breast cancer, CT chemotherapy, LDH Lactate
Deshydrogenase, CEA Carcinoembryonic Antigen, CA 15-3 Cancer Antigen 15-
3, HER2-ECD HER2 extra-cellular domain, NSE Neuron Specific Enolase, MMP-9
Matrix Metalloproteinase 9
a lobular carcinoma (n = 21), mucinous carcinoma (n = 1), papillary carcinoma
(n = 3), medullary carcinoma (n = 1), mixed ductal and lobular carcinoma (n =
12), other histological subtypes (n = 4)
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Table 2 Univariate analysis




Tumor biology group <0.001
HER2+ HR+ 32.1 (16.5 – NC)
HER2+ HR- 28.7 (19.1–34.5)
HER2- HR+ 12.5 (10.4–22.8)











Ductal carcinoma 15.2 (11.6–20.6)
All other subtypes 20.1 (10.1–35.6)
Histological grade (SBR) 0.024




Yes 20.9 (6.8 – NC)
Metastatic status at BC diagnosis 0.012
M0 13.6 (10.4–16.5)
M1 27.2 (13.7–32.1)
Characteristics at the time of the serum sample
Age group 0.723
< 50 15.0 (10.0–23.0)
50 to 70 16.3 (11.6–20.7)
> 70 20.2 (9.7–51.4)
ECOG status <0.001
Score 0 34.5 (20.9–53.4)
Score 1 16.5 (12.1–22.5)
Score 2 8.5 (3.8–16.8)
Score 3 2.0 (1.4–4.6)
Number of lines of CT <0.001
0 line 17.6 (14.8–27.2)
1 or 2 line(s) 22.8 (16.8–32.1)
> 2 lines 6.4 (4.6–10.4)
Previous anti-HER2 treatment <0.001
No 11.7 (9.8–15.2)
Table 2 Univariate analysis (Continued)
Yes 28.7 (20.1–33.9)
Metastatic-free interval 0.464
≤ 24 months 14.8 (10.6–20.7)
> 24 months 16.5 (12.4–23.3)
Number of metastatic sites <0.001
1 59.2 (23.0 – NC)
> 2 13.3 (11.1–16.8)
Location of metastatic sites 0.001


































Yes 10.4 (5.2 – NC)
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phenomenon could be explained by an increase in the
ECD cleaving, leading at the same time to an increase of
serum ECD and of a negative HER2 tumor phenotype.
We can thus hypothesize that the prognostic value of
serum HER2 ECD in HER2-negative tumors could be
linked in part to the subset of patients with “false”
HER2-negativity, that is, patients without HER2 ECD ex-
pression but with expression of its intracellular, acti-
vated, domain.
The prognostic value of S100ß in MBC has been
scarcely investigated in breast cancer so far, while it has
been well demonstrated in melanoma [29]. We found
high serum S100ß to be an independent unfavorable
prognostic factor. This is concordant with the results of
another study on a series of 80 EBC and MBC patients
[42]. In this study, elevated serum S100ß (cut-off
0.12 μg/L) was a significant predictor of poor disease-
free survival. However, our result must be considered
with caution as the two groups identified by S100ß
serum levels were grossly unbalanced regarding the
number of patients (n = 19 for S100ß > 0.12 μg/L com-
pared to n = 224 for normal S100ß). Despite its signifi-
cant prognostic value in multivariate analysis, its clinical
impact is questionable, as rarely elevated biomarkers ap-
pear to be of limited usefulness in clinical practice. It is
interesting to note that the analysis of S100ß with the
cut-off of 0.072 μg/L, even though it defined two more
balanced groups regarding the number of patients, did
not reach significance in multivariate analysis. Our study
has included a high number of patients with BM (35 %,
as discussed in the “limitations” section), and BM are as-
sociated with a poor outcome. Among these patients, 73
(82.9 %) had a S100ß serum level > 0.12 μg/L. It could
thus be hypothesized that the negative prognostic impact
of high serum S100ß is linked to the presence of BM.
However, the serum S100ß was not predictive of BM in
a series of 101 patients with BC [33]. This question is
also being studied in another article from our team
(under review).
We found that neither NSE nor MMP-9 serum levels
were correlated with outcomes. The prognostic value of
serum NSE in MBC patients had, to our knowledge,
never been studied before. Despite its prognostic value
in univariate analysis, we found that it was not an inde-
pendent prognostic factor in this population.
High serum MMP-9 has been associated with poor
disease-free survival and OS in previous studies in breast
cancer patients [25, 35]. We found a reverse association
in univariate analysis: patients with high serum MMP-9
had a better outcome in our study. However, MMP-9
did not remain an independent prognostic factor in
multivariate analysis. Several hypotheses can be made to
explain this discordant result. First, it could be due to
differences in the population’s initial characteristics, as







Serum protein level 0.780
Normal 9.7 (5.2–11.6)
Low 6.4 (2.3–13.6)









Elevated CA 15-3 <0.001
Normal 28.7 (20.1–59.2)
Elevated 11.3 (9.7–14.4)
Serum HER2 (cut-off 15 ng/mL) <0.001
Normal 22.6 (16.2–32.3)
Elevated 11.3 (8.9–14.4)
Serum HER2 (cut-off 30 ng/mL) <0.001
Normal 20.2 (15.0–28.6)
Elevated 10.1 (5.2–13.6)
Serum NSE (cut-off 12.5 μg/L) <0.001
Normal 20.6 (16.2–30.4)
Elevated 9.9 (5.6–14.4)
Serum MMP9 (cut-off 50 ng/mL) 0.009
Normal 3.8 (1.1 – NC)
Elevated 16.2 (12.5–20.7)
Serum S100ß (cut-off 0.12 μg/L) <0.001
Normal 17.2 (14.4–22.6)
Elevated 4.5 (1.6–10.0)
Serum S100ß (cut-off 0.072 μg/L) <0.001
Normal 20.3 (15.1–30.4)
Elevated 6.2 (4.5–12.1)
Abbreviations: ER estrogen-receptors, PR progesterone-receptors, SB Scarf,
Bloom and Richardson, BC breast cancer, CT chemotherapy, LDH Lactate
Deshydrogenase, CEA Carcinoembryonic Antigen, CA 15-3 Cancer Antigen
15-3, HER2-ECD HER2-extra-cellular domain, NSE Neuron Specific Enolase,
MMP-9 Matrix Metalloproteinase 9
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Fig. 1 Overall survival (OS) according to a the tumor biological subtype, b the ECOG performance status, c the presence of brain metastases,
d the presence of subcutaneous metastases, e the number of previous chemotherapy lines, f the serum CA 15-3 level, g the serum HER2 ECD
level, and h the serum S100ß level. *NC: not calculable
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the study by Sung et al. evaluated MMP-9 tissue expres-
sion in EBC, while our study included advanced MBC
patients [25]. One can thus hypothesize a differential ef-
fect between the role of MMP-9 in invasion (linked to
EBC relapse) and its lack of prognostic impact in later
stage MBC, for whom the invasion and metastatic
process has already been set. Another explanation could
be linked to the different method of MMP-9 evaluation,
based in one of the previous studies on tissue expres-
sion, and on serum levels in our present study. Other
limitation for the analysis of the prognostic impact of
MMP-9 on outcomes is the absence of a validated cut-
off. We used a previously reported cut-off of 50 ng/mL,
but other cut-offs may be more pertinent [35]. Finally,
the two groups defined by MMP-9 serum levels in our
study were very unbalanced (n = 6 for MMP-9 ≤ 50 ng/
mL compared with n = 244 for MMP-9 > 50 ng/mL),
which may explain our negative results. Serum MMP-9
being elevated in a vast majority of patients, its clinical
usefulness is questionable.
Prognostic value of other biological parameters
The classical prognostic value of HR status was
confirmed in our study (median OS 22.8 months for PR-
positive tumors compared with 12.5 months for PR-
negative tumors; p = 0.035) [4, 7, 8]. Concerning the ER
status, this difference in OS did not reach significance,
which can be explained by the fact that PR positivity en-
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p<0.0001
Fig. 2 Overall survival (OS) according to the serum HER2 ECD level (with cut-off 15 ng/mL) in the HER-positive and HER2-negative populations.
*NC: not calculable
Table 3 Multivariate Cox regression analyses (Stepwise
procedure)
Parameter Hazard-ratio 95 % CI P-value
Performance status:
ECOG 0 1
ECOG 1 1.75 1.12–2.73 0.013
ECOG 2 2.62 1.51–4.53 0.001
ECOG 3 9.78 4.85–19.73 <0.001
Tumor biology:
HER2+/HR+ 1
HER2+/HR− 1.19 0.70–2.04 0.514
HER2−/HR+ 2.49 1.49–4.18 0.001
Triple negative 5.31 2.97–9.47 <0.001
Number of previous metastatic CT lines:
0 1
1 or 2 1.81 1.14–2.86 0.012
> 2 2.57 1.57–4.21 <0.001
Brain metastases 2.26 1.57–3.25 <0.001
Subcutaneous metastases 1.92 1.22–3.01 0.005
Elevated CA 15-3 (cut-off 30 UI/L) 1.95 1.31–2.93 0.001
Elevated HER2 ECD (cut-off 30 ng/mL) 2.51 1.53–4.12 <0.001
Elevated S100ß (cut-off 0.12 μg/L) 1.93 1.05–3.54 0.033
Abbreviations: ECOG Eastern Cooperative Oncology Group, CT chemotherapy,
CA 15-3 Cancer Antigen 15-3, HER2-ECD HER2-extra-cellular domain
Darlix et al. BMC Cancer  (2016) 16:428 Page 10 of 14
ER-positive tumors, and appears in different studies as a
strong indicator of ER sensitivity.
Regarding the tumor HER2 status, we found that the
presence of HER2 hyper-expression/amplification was an
independent favorable prognostic factor in MBC. Me-
dian OS was 31.6 months in the HER2-positive group
compared with 10.4 months in the HER2-negative group
(p < 0.001). This result is concordant with that of other
recent studies (considering the 2008–2015 inclusion
period of our study) conducted in the Trastuzumab field,
but discordant with pre-Trastuzumab studies [9, 10]. In-
deed, in the study published by Dawood et al., the out-
come was more favorable in patients with HER2-positive
tumors treated with Trastuzumab than in patients with
HER2-positive tumors not receiving Trastuzumab, or
than in patients with HER2-negative tumors [10]. In our
study, patients who had received a previous anti-HER2
treatment had, indeed, a better outcome (median OS
28.7 months compared with 11.7 months for patients
not receiving anti-HER2 treatments, p < 0.001).
We found significant differences in median OS be-
tween the four biological groups of tumors, confirming
previous data. Patients with HER2+/HR+ tumors have
the best outcome, with a median OS of 32.1 months in
our study, consistent with the 34.4 month median OS
reported in a previous study [5]. Triple negative tumors
have the most dismal outcome, with a median OS of
7.6 months in our study consistent with the 8.8 month
median OS previously reported [5]. HER2+/HR- and
HER2-/HR+ tumors present with an intermediate sur-
vival (median OS of 28.7 months and 12.5 months, re-
spectively). In the study published by Lobbezoo et al.,
patients with HER2-/HR+ tumors had a better outcome
than patients with HER2+/HR- tumors, conversely to
what was found in our study [5]. This difference could
have two explanations. First, only 27.0 % of patients with
HER2-positive tumors received Trastuzumab in this
study, compared 83.2 % in our study (and only 37.5 %
versus 80.3 % of patients with HER+/HR- tumors, in the
Lobbezoo et al. study and the present work, respect-
ively). Moreover, a more heterogeneous population of
patients was included in our study, with a variable num-
ber of previous CT lines (range 0–9), whereas Lobbezoo
et al. have investigated prognostic factors at the time of
the diagnosis of the metastatic disease.
Other primary tumor characteristics, such as the histo-
logical subtype or the histological grade, were not corre-
lated with the patients’ prognosis. This is concordant
with results from other large studies in MBC [5, 11, 43].
However the histological grade was shown to have a
prognostic value in other studies [4, 44].
Serum LDH was not found to be predictive of the pa-
tients’ outcomes in both univariate and multivariate ana-
lysis, which is discordant with the results of other
studies [11, 13]. The high proportion of missing data (n =
160) probably explains our result. Also due to a high num-
ber of missing data, the albumin serum level could not be
included in the multivariate Cox model, however a high
level had a negative prognostic value in univariate analysis,
and has been reported as an independent prognostic fac-
tor of poor outcome in previous studies [12, 13].
Clinical prognostic factors
Among clinical parameters associated with MBC patients’
outcome, the number of metastatic sites and the meta-
static sites involved are both of high value. The presence
of bone and/or subcutaneous metastases are associated
with a better outcome (median OS >33 months) com-
pared with the presence of multiple or visceral metastases
(median OS 22 months) [6]. In our study, the occurrence
of visceral metastases (compared with bone and/or sub-
cutaneous metastases only) was a poor prognostic factor,
however this results must be considered with caution
as only few patients had isolated bone and/or subcuta-
neous metastases (n = 13), due to a high proportion of
patients with advanced MBC. The presence of BM was
associated with a poor outcome in our study (median
OS of 9.7 months compared with 30.4 months, p <
0.001), as shown in previous studies [4]. However, the
presence of liver metastases was associated with poor
prognosis in univariate but not multivariate analyses,
while its poor prognostic value has been demonstrated
in previous studies [4]. This difference may be due to
the over-representation of BM in our study. As shown
in previous studies, a high number of metastatic sites
was a poor prognostic determinant in univariate but
not in multivariate analyses [7].
Surprisingly, we found that de novo MBC (compared
to metachronous metastatic disease) was associated with
a better outcome in univariate analysis. A trend favoring
de novo MBC was also found in a study published by
Lobbezoo et al., with a median OS of 21.1 months for
patients with metachronous metastatic progression com-
pared with 29.4 months for patients with de novo MBC
(p = 0.14) [45]. In this study, the prognostic impact of
the MFI was also investigated: de novo MBC patients
had a better outcome than patients with a MFI <
24 months, but no difference in OS was reported when
comparing de novo MBC patients with patients who had
a MFI > 24 months, advocating for the identification of
this short MFI group as a highly aggressive, resistant,
tumor subset [44]. These results are somewhat discord-
ant with numerous other studies that have shown that
patients with a MFI < 24 months had a poorer outcome
compared with patients with a MFI ≥ 24 months [4, 7, 8,
11]. However, in these studies, patients with a synchron-
ous metastatic disease were classified into the MFI <
24 months group, possibly diluting the positive prognostic
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impact of synchronous metastases within the short MFI
group. In our study, we found no difference in OS among
patients according to the MFI (p = 0.464).
The number of previous metastatic CT lines was also
an independent prognostic determinant in our study. Pa-
tients with no previous CT line had a better outcome
compared to those having received one or two CT
line(s), or >2 lines, which is concordant with previously
published data [7].
Limitations
Our study is based on a well-characterized series of
MBC patients and brings new data on additional tumors
markers and their prognostic value. Nevertheless, it pre-
sents some limitations. Due to its retrospective nature,
we could not avoid having some missing data, in par-
ticular for classical biological parameters such as LDH
or albumin. Moreover, patients in our study were identi-
fied for the purposes of a case-control study in MBC pa-
tients with BM, therefore there is in our series an over-
representation of these patients, and, as a consequence,
of patients with a HER2-positive tumor. Indeed, 35 % of
patients had BM, compared to a few percent in other
studies [4, 5]. This result causes an obvious bias regard-
ing the survival analyses. The median OS in our study
was indeed lower than in previous works: 16.2 months
compared with 23.1 months and 21.8 months in the
studies published by Largillier et al. and Lobbezoo et al.,
respectively [4, 5]. This difference can also be explained
by the fact that patients in our series had a more ad-
vanced disease. Indeed, 30.4 % of patients had an ad-
vanced metastatic disease (>2 previous CT lines) while
patients in the Lobbezoo et al. study were included at
the diagnosis of the metastatic disease [5]. As regards
the HER2 tumor status, a high proportion (47.6 %) of
patients had a HER2-positive tumor, whereas this pro-
portion is usually around 20 % in various studies [4, 5].
Therefore, our population may not have been entirely
representative of a routine MBC population. However,
the analysis on the 162 MBC patients without BM con-
firmed that high serum CA 15-3 (p < 0.001), HER2 ECD
(p < 0.001) and S100ß (p < 0.001) levels were associated
with poor survival.
Conclusions
In conclusion, serum CA 15-3, HER2 ECD and S100ß
levels could represent useful independent prognostic fac-
tors in MBC. A validation of these results in an inde-
pendent set of MBC samples is necessary to confirm
these findings. Of particular interest is the independent
prognostic value of serum HER2 ECD level, independ-
ently of the tumor HER2 status, possibly linked to meta-
static tumor heterogeneity or presence of HER2 ECD
negative/HER2 intracellular activated tumors.
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